Clinicopathological characteristics and prognosis of sequential primary cancers of the breast and ovarian: report of 44 cases
10.3760/cma.j.issn.1007-631X.2016.06.014
- VernacularTitle:44例乳腺卵巢双原发癌的临床特点与预后分析
- Author:
Li ZHENG
;
Lina ZHANG
;
Lin GU
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Ovarian neoplasms;
Prognosis
- From:
Chinese Journal of General Surgery
2016;31(6):482-485
- CountryChina
- Language:Chinese
-
Abstract:
Objective To identify the relationship between the clinical characteristics and prognostic factors in sequentially occurring primary cancers of the breast and ovarian.Methods Clinical and pathological data of 44 cases of successive primary cancers of the breast and ovarian in each single patient diagnosed in Tianjin Medical University Cancer Institute and Hospital from 2000 to 2013 were retrospectively analyzed.Results The median overall survival of all patients with double primary cancers of breast and ovarian was 264 months.3-year overall survival rate was 95.3％ and 5-year overall survival rate was 83.0％ respectively.32 patients were first diagnosed with breast cancer and 12 patients firstly suffered from ovarian cancer.The interval between breast cancer and ovarian cancer was 1-240 months (median 60 months).The staging of ovarian cancer (P =0.005) is the main prognostic factor.In patients firstly diagnosed breast cancer,age (P =0.025) and chemotherapy(P =0.010) were mainly associated with the interval between breast cancer and ovarian cancer.Age when first cancer diagnosed,tumor size of the breast and staging of ovarian cancer were mainly prognostic factors.Age when breast cancer diagnosed and chemotherapy were factors impacting the interval of breast cancer and ovarian cancer.Conclusions For patients with sequentially diagnosed primary cancers of the breast and ovarian cancer,late stage ovarian cancer predicts a poor prognosis.The interval in patients aged 50 and below suffering from secondary cancer is long.Proper chemotherapy for breast cancer seems to delay the occuring of ovarian cancer.
